Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33225317.
- Also identified by DOI 10.1016/j.xcrm.2020.100145 and PMC identifier 7670931.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A screen by Kost-Alimova et al.<sup>1</sup> suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
Medical subject headings
- Acute Lung Injury
- Aminopyridines
- Drug Repositioning
- Morpholines
- Pyrimidines
- SARS-CoV-2
- COVID-19 Drug Treatment